Abstract:Objective To observe the clinical effect and safety of dupilumab in the treatment of generalized bullous pemphigoid (BP). Methods The clinical data of patients with generalized BP admitted to the Department of Dermatology of Northeast International Hospital from November 2021 to November 2022 were retrospectively analyzed. Results Among the 10 cases, 5 were male and 5 were female, aged 44-91 (73.5±12.8) years, the course of disease was 7-240 (95.2±85.2) days. The underlying diseases included diabetes mellitus (4 cases), coronary heart disease (4 cases), cardiac insufficiency (1 case), hypertension (7 cases), cerebral hemorrhage (1 case), cerebral infarction (2 cases) and rectal cancer (1 case). Combined with typical clinical manifestations, histopathology, and direct/indirect immunofluorescence, the clinical diagnosis was generalized BP. All patients were treated with subcutaneous injection of dupilumab, 600 mg for the first time and 300 mg every 2 weeks thereafter, and according to the clinical manifestations, the traditional treatment drugs were gradually reduced and discontinued. All patients BP disease area index (BPDAI) score, body surface area (BSA) and itch numerical rating scale (NRS) scores were reduced to 0. No recurrence was observed during 6-12 months of follow-up. Conclusion Dupilumab is effective and safe in the treatment of generalized BP with multiple systemic lesions.